NCT01853020

Cannabinoids and Cerebellar-Motor Functioning

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 21 Years – 35 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to characterize the dose-related effects of delta-9-tetrahydrocannabinol (∆9-THC) in healthy individuals on cerebellum-dependent motor functions.

Detailed description

The overall aim of the current proposal is to investigate whether acute, IV ∆9-THC administration mediates cerebellar versus forebrain-dependent associative learning in humans as assessed with eyeblink conditioning (EBC). In addition, a battery of motor function tests will also be administered (the CANTAB motor screening test, Grooved Pegboard Motor Task, paced finger tapping).

Conditions

• Cannabis
• Psychotic Disorders

Interventions

Type	Name	Description
DRUG	THC	Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes. Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or "joint". Administered intravenously over 10 minutes. Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or "joint". Administered intravenously over 10 minutes.
DRUG	Placebo	Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.

Timeline

• Start date: 2012-12-01
• Primary completion: 2015-04-07
• Completion: 2015-04-07
• First posted: 2013-05-14
• Last updated: 2024-09-19

Locations

1 site across 1 country: United States